Termicon, cream 1% 15 g

Termicon is an antifungal drug, allylamine. It has a wide range of antifungal action.

It is active against dermatophytes: Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Trichophyton verrucosum, Trichophyton violaceum, Microsporum canis, Epidermophyton floccosum. In low concentrations has a fungicidal effect on dermatophytes, mold fungi (including Aspergillus, Cladosporium, Scopulariopsis brevicaulis) and some dimorphic fungi. On yeast fungi of the genus Candida (mainly Candida albicans) and their mycelial forms, depending on the species, the drug has fungicidal or fungistatic effect.

Termicon disrupts the early stage of biosynthesis of the main component of the cell membrane of the fungus ergosterol by inhibiting the enzyme squalene epoxidase. This leads to ergosterol deficiency and intracellular accumulation of squalene, which causes cell death of the fungus. The action of terbinafine is performed by inhibiting the enzyme squaleneepoxidase located on the cell membrane of the fungus.

Pharmacokinetics

When applied topically, absorption is less than 5% and has little systemic effect.

Indications

Active ingredient

Composition

1 g cream contains:

Active substance:

terbinafine hydrochloride – 10 mg;

Associates:

Cetyl alcohol (lanet 16),

stearyl alcohol or cetostearyl alcohol (lanet “0” coarse),

benzyl alcohol,

cetylpalmitate (cutin SR),

polysorbate 60,

isopropyl myristate,

br>

sorbitan stearate,

sodium hydroxide,

purified water.

How to take, the dosage

Termicon® is used topically in adults and children over 12 years of age.

The affected areas should be cleaned and dried before applying the cream. The cream is applied 1-2 times a day with a thin layer on the affected skin and adjacent areas and rubbed in gently.

Infections accompanied by diaper rash (under the breasts, between the fingers, between the buttocks, in the groin area), the spots where the cream is applied can be covered with gauze, especially at night.

The average duration of treatment in dermatomycosis of the trunk, shins, feet – once a day for 1 week; in candidiasis of the skin – 1-2 times a day for 1-2 weeks; in lichen planus – 1-2 times a day for 2 weeks.

Development of clinical manifestations is usually noted in the first days of treatment. If treatment is irregular or if it is discontinued prematurely, there is a risk of a recurrence of the infection. If no signs of improvement are noted after 1-2 weeks of treatment, the diagnosis must be verified.

The dosing regimen for elderly patients is the same as for patients in other age groups.

Special Instructions

A reduction in the severity of clinical manifestations is usually noted in the first days of treatment. If treatment is intermittent or discontinued prematurely, there is a risk of recurrence of the infection.

Termicon cream is for external use only.

Please avoid getting it in the eyes, as it may cause irritation. If you accidentally get the product in your eyes, flush them immediately with running water, and consult a physician if persistent irritation develops.

In case of allergic reactions the drug should be discontinued.

Contraindications

Hypersensitivity to the components of the drug.

With caution: the drug should be used in cases of hepatic and/or renal insufficiency, alcoholism, bone marrow hematopoiesis suppression, tumors, metabolic diseases, occlusive diseases of limb vessels, in children under 12 years of age (lack of sufficient clinical experience).

Side effects

Local reactions: redness, itching or burning sensation, allergic reactions may occur where the cream is applied.

Overdose

No cases of drug overdose have been reported. If Termicon® is accidentally ingested, the same symptoms can be expected as in case of tablet overdose: headache, nausea, epigastric pain and dizziness.

Treatment: activated charcoal, if necessary, symptomatic supportive therapy.

Pregnancy use

Termicon should be used under strict indications and if the estimated benefit to the mother exceeds the potential risk to the fetus.

In experimental studies terbinafine teratogenic properties have not been revealed. To date, no malformations have been reported when using Termicon.

Terbinafine is excreted with breast milk. However, when Termicon spray is used by a nursing mother, a small amount of the active ingredient is absorbed through the skin, so adverse effects on the infant are unlikely.

Similarities